137 related articles for article (PubMed ID: 23059870)
1. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.
Finocchiaro LM; Glikin GC
Cancer Gene Ther; 2012 Dec; 19(12):852-61. PubMed ID: 23059870
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.
Finocchiaro LM; Fondello C; Gil-Cardeza ML; Rossi ÚA; Villaverde MS; Riveros MD; Glikin GC
Hum Gene Ther; 2015 Jun; 26(6):367-76. PubMed ID: 25762364
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.
Finocchiaro LM; Glikin GC
Gene Ther; 2008 Feb; 15(4):267-76. PubMed ID: 18033308
[TBL] [Abstract][Full Text] [Related]
4. Combination of cytokine-enhanced vaccine and chemo-gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.
Finocchiaro LME; Agnetti L; Fondello C; Glikin GC
Gene Ther; 2019 Nov; 26(10-11):418-431. PubMed ID: 30858538
[TBL] [Abstract][Full Text] [Related]
5. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma.
Finocchiaro LM; Fiszman GL; Karara AL; Glikin GC
Cancer Gene Ther; 2008 Mar; 15(3):165-72. PubMed ID: 18219342
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas.
Finocchiaro LM; Villaverde MS; Gil-Cardeza ML; Riveros MD; Glikin GC
Res Vet Sci; 2011 Oct; 91(2):230-4. PubMed ID: 21300385
[TBL] [Abstract][Full Text] [Related]
8. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.
Dow SW; Elmslie RE; Willson AP; Roche L; Gorman C; Potter TA
J Clin Invest; 1998 Jun; 101(11):2406-14. PubMed ID: 9616212
[TBL] [Abstract][Full Text] [Related]
9. Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting.
Villaverde MS; Combe K; Duchene AG; Wei MX; Glikin GC; Finocchiaro LM
Int Immunopharmacol; 2014 Sep; 22(1):167-75. PubMed ID: 24973616
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.
Quintin-Colonna F; Devauchelle P; Fradelizi D; Mourot B; Faure T; Kourilsky P; Roth C; Mehtali M
Gene Ther; 1996 Dec; 3(12):1104-12. PubMed ID: 8986437
[TBL] [Abstract][Full Text] [Related]
15. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
Hawkins WG; Gold JS; Blachere NE; Bowne WB; Hoos A; Lewis JJ; Houghton AN
J Surg Res; 2002 Feb; 102(2):137-43. PubMed ID: 11796010
[TBL] [Abstract][Full Text] [Related]
16. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
17. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
18. [Combined use of irradiation and DNA tumor vaccine to treat canine oral malignant melanoma: a pilot study].
Herzog A; Buchholz J; Ruess-Melzer K; Lang J; Kaser-Hotz B
Schweiz Arch Tierheilkd; 2013 Feb; 155(2):135-42. PubMed ID: 23385072
[TBL] [Abstract][Full Text] [Related]
19. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
20. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
